Our study indicated that the development of anorexia, hypertension, pneumothorax, and hypothyroidism might be potential signs for the efficacy following apatinib-treated refractory osteosarcoma. These AEs arising early in the treatment course, which are mild or moderate and are manageable by patient monitoring and supportive care, would predict better prognosis.

Trial Registration

Continue Reading

Prospectively registered in the Medical Ethics Committee of Peking University People’s Hospital. The trial registration number is 2015PHB176-01 and the date of registration is March 15th 2016.

Ethics Approval and Consent to Participate

The study was approved by the Institutional Review Board of Peking University People’s Hospital (Beijing, China), and was conducted in accordance with the provisions of the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good Clinical Practice.

Patient Consent for Publication

All of the patients provided written informed consent for publication of their data. However, because they were all in Chinese, the English version of their consents are not applicable.

Data Sharing Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author Contributions

Lu Xie, Jie Xu, and Wei Guo designed and developed the trial. Wei Guo, Xiaodong Tang, Rongli Yang, and Taiqiang Yan were responsible for patient inclusion. Lu Xie, Jie Xu, and Xin Sun collected data. Lu Xie, Jie Xu, and Wei Guo analyzed and interpreted the data. Lu Xie wrote the manuscript. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.


The authors declare that they have no conflicts of interest.

Lu Xie, Jie Xu, Xin Sun, Xiaodong Tang, Taiqiang Yan, Rongli Yang, Wei Guo

Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, People’s Republic of China

Correspondence: Wei Guo
Musculoskeletal Tumor Center, Peking University People’s Hospital, Xicheng District, Beijing 100044, People’s Republic of China
Tel +86-13701195504
Email [email protected]


1. Xie L, Ji T, Guo W. Anti-angiogenesis target therapy for advanced osteosarcoma. Oncol Rep. 2017;38(2):625–636. doi:10.3892/or.2017.5735

2. Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised Phase 2 clinical trial. Lancet Oncol. 2015;16(1):98–107. doi:10.1016/S1470-2045(14)71136-2

3. Grignani G, Palmerini E, Dileo P, et al. A Phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian sarcoma group study. Ann Oncol. 2011;23(2):508–516. doi:10.1093/annonc/mdr151

4. Li F, Liao Z, Zhang C, et al. Apatinib as targeted therapy for sarcoma. Oncotarget. 2018;9(36):24548–24560. doi:10.18632/oncotarget.v9i36

5. Xie L, Guo W, Wang Y, Yan T, Ji T, Xu J. Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China. BMC Cancer. 2018;18(1):396. doi:10.1186/s12885-018-4303-z

6. Zhu B, Li J, Xie Q, Diao L, Gai L, Yang W. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther. 2018;19(3):198–204. doi:10.1080/15384047.2017.1416275

7. Li F, Liao Z, Zhao J, et al. Efficacy and safety of apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget. 2017;8(38):64471–64480. doi:10.18632/oncotarget.16293

8. Lee HJ, Moon JY, Baek SW. Is treatment-emergent toxicity a sign of efficacy of apatinib in gastric cancer? J Clin Oncol. 2016;34(31):3823. doi:10.1200/JCO.2016.68.8663

9. Zhang S. Problematic analysis and inadequate toxicity data in Phase III apatinib trial in gastric cancer. J Clin Oncol. 2016;34(31):3821. doi:10.1200/JCO.2016.67.3889

10. Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219–3225. doi:10.1200/JCO.2013.48.8585

11. Yamamoto K, Mizumoto A, Nishimura K, et al. Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). PLoS One. 2014;9(7):e102110. doi:10.1371/journal.pone.0102110

12. Poprach A, Pavlik T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol. 2012;23(12):3137–3143. doi:10.1093/annonc/mds145

13. Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care. 2009;3(3):170–179. doi:10.1097/SPC.0b013e32832e4681

14. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–5212. doi:10.1200/JCO.2007.15.6331

15. Dreno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28(5):1137–1144. doi:10.1093/annonc/mdx040

16. Jain L, Sissung TM, Danesi R, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res. 2010;29:95. doi:10.1186/1756-9966-29-95

17. Interiano RB, McCarville MB, Wu J, Davidoff AM, Sandoval J, Navid F. Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. J Pediatr Surg. 2015;50(9):1484–1489. doi:10.1016/j.jpedsurg.2015.01.005

18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026

19. National Institutes of Health NCI. Common terminology criteria for adverse events (CTCAE) Version 4.0. Common Terminology Criteria for Adverse Events (CTCAE); 2009: 1–196.

20. Mols F, Husson O, Oudejans M, Vlooswijk C, Horevoorts N, van de Poll-franse LV. Reference data of the EORTC QLQ-C30 questionnaire: five consecutive annual assessments of approximately 2000 representative Dutch men and women. Acta Oncol. 2018;57:1–11.

21. Taarnhoj GA, Kennedy FR, Absolom KL, et al. Comparison of EORTC QLQ-C30 and PRO-CTCAE questionnaires on six symptom items. J Pain Symptom Manage. 2018;56(3):421–429. doi:10.1016/j.jpainsymman.2018.05.017

22. Wallwiener M, Matthies L, Simoes E, et al. Reliability of an e-PRO tool of EORTC QLQ-C30 for measurement of health-related quality of life in patients with breast cancer: prospective randomized trial. J Med Internet Res. 2017;19(9):e322. doi:10.2196/jmir.8210

23. Rosas S, Paco M, Lemos C, Pinho T. Comparison between the visual analog scale and the numerical rating scale in the perception of esthetics and pain. Int Orthod. 2017;15(4):543–560.

24. Tsze DS, von Baeyer CL, Pahalyants V, Dayan PS. Validity and reliability of the verbal numerical rating scale for children aged 4 to 17 years with acute pain. Ann Emerg Med. 2018;71(6):691–702. doi:10.1016/j.annemergmed.2017.09.009

25. Agharanya JC. Clinical usefulness of ELISA technique in the assessment of thyroid function. West Afr J Med. 1990;9(4):258–263.

26. Huang P, Ou AH, Piantadosi S, Tan M. Formulating appropriate statistical hypotheses for treatment comparison in clinical trial design and analysis. Contemp Clin Trials Commun. 2014;39(2):294–302. doi:10.1016/j.cct.2014.09.005

27. Xie L, Xu J, Sun X, et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase 2 clinical trial. Oncologist. 2019;24:e542–e550. doi:10.1634/theoncologist.2018-0542

28. Agulnik M, Attia S. Growing role of regorafenib in the treatment of patients with sarcoma. Target Oncol. 2018;13:1–6.

29. Healey JH. Regorafenib: efficacy in multiple refractory sarcoma types. Lancet Oncol. 2016;17(12):1633–1634. doi:10.1016/S1470-2045(16)30509-5

30. Beuselinck B, Karadimou A, Lambrechts D, et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2013;108(4):887–900. doi:10.1038/bjc.2012.548

31. Miles DW, de Haas SL, Dirix LY, et al. Biomarker results from the AVADO Phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108(5):1052–1060. doi:10.1038/bjc.2013.69

32. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26(28):4672–4678. doi:10.1200/JCO.2008.16.1612

33. Fan M, Zhang J, Wang Z, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 2014;143(1):141–151. doi:10.1007/s10549-013-2793-6

34. Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011;117(3):534–544. doi:10.1002/cncr.v117.3

35. Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol. 2012;30(5):704–710. doi:10.1016/j.urolonc.2010.07.015

36. Shinohara N, Takahashi M, Kamishima T, et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer. 2011;104(2):241–247. doi:10.1038/sj.bjc.6606029

37. Makita N, Iiri T. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid. 2013;23(2):151–159. doi:10.1089/thy.2012.0456

38. Robinson ES, Matulonis UA, Ivy P, et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010;5(3):477–483. doi:10.2215/CJN.08111109

39. Horowitz JR, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997;17(11):2793–2800. doi:10.1161/01.ATV.17.11.2793

40. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54(3):652–658. doi:10.1161/HYPERTENSIONAHA.109.129973

Source: Cancer Management and Research.
Originally published January 7, 2019.

READ FULL ARTICLE Curated publisher From Dovepress